Aurinia Pharma
Newark, PA, United States
Dr. Simon Zhou is currently the Vice President of Pharmacology and Pharmacometricst at Aurinia Pharma. In this capacity, he is responsible for a group of clinical pharmacologists and pharmacometricians conducting clinical pharmacology and pharmacometric characterization of drug candidates from phase I to phase IV. He is experienced in development and implementation of overall clinical development strategy to profile clinical pharmacokinetics, biopharmaceutics, pharmacodynamics and exposure-response of drug candidates, design and analysis of clinical protocols, submission of INDs and NDAs and interaction with regulatory agencies around the globe. Prior to his current position, he has worked in preclinical and clinical drug development functions addressing clinical pharmacology, biopharmaceutical and trial design issues at hCelegne, hWyeth, Pfizer and Bristol-Myers Squibb.
Dr. Zhou has received recognition and awards in Celgene, hWyeth, and Bristol-Myers Squibb for his work to advance drug candidates in clinical development and obtain regulatory approval of ABECMA®, BREYANZI®, ONUREG®, REBLOZYL®, INREBIC®, OTEZLA®, POMALYST® and IDHIFA®, expanded indications, patent extension and new formulations of Irbesartan, Fosinopril, Enbrel, Revelimid and Abraxane. He has published over 50 manuscripts in biopharmaceutics, drug delivery and pharmacokinetic and pharmacodynamic modeling. Dr. Zhou holds BS and MS in chemistry, a Ph.D. in Pharmaceutics.
0601: Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure information not submitted.
